OncoMatch/Clinical Trials/NCT07092514
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Is NCT07092514 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lenvatinib for thyroid cancer.
Treatment: Lenvatinib — This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: VEGF/VEGFR targeted therapy (sorafenib, pazopanib, vandetinib, axitinib, sunitinib, cabozantinib)
Exception: No more than 1 prior line for DTC
No more than 1 prior line of VEGF/VEGFR targeted therapy for DTC. Examples of VEGF/VEGFR therapies include sorafenib, pazopanib, vandetinib, axitinib, sunitinib, and cabozantinib, but others exist.
Cannot have received: VEGFR inhibitor (lenvatinib)
Prior treatment with lenvatinib [excluded].
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 100 K/cumm; Hemoglobin ≥ 9.0 g/dL
Kidney function
Creatinine clearance > 30 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN (5.0 x IULN in the presence of hepatic metastases)
Cardiac function
QTcF < 481 msec; NYHA class 2B or better required for patients with cardiac disease or history of cardiotoxic agents
Adequate bone marrow and organ function as defined below: Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 100 K/cumm; Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN (5.0 x IULN in the presence of hepatic metastases); Creatinine clearance > 30 mL/min by Cockcroft-Gault; UPC ≤ 1000 mg/G; QTcF < 481 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify